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Controlled proteolysis is key to bacterial viability. In this issue ofChemistry &Biology, Gavrish and colleagues
characterize a natural product, lassomycin, targeting theMycobacterium tuberculosis caseinolytic (Clp) pro-
tease. Unusually, lassomycin activates ClpC1, inducing ATPase activity and decoupling it from proteolysis.Mycobacterium tuberculosis, the causa-
tive agent of tuberculosis (TB), remains a
major threat to human health. The prob-
lem of antibiotic resistance in TB cannot
be understated, because the proportion
and severity of multidrug resistant isolates
is growing. In addition, the current TB
treatments are complex and lengthy,
usually no shorter than 6 months. There-
fore, there is a general desire to shorten
therapy by targeting bacteria in diverse
physiological states more representative
of the natural infection. The urgent need
to develop new antitubercular agents to
address issues of resistance and treat-
ment duration has led to increased efforts
in phenotypic screening. Much of this has
focused on small molecule libraries in
order to find drug-like molecules that
can be progressed quickly, although
natural products also represent a source
of chemical diversity.
In this issue of Chemistry &
Biology, Gavrish et al. (2014) identify a
novel natural product, lassomycin, with
potent and specific activity against
M. tuberculosis working via the caseino-
lytic protease (Clp). Clp plays a major
role in degrading proteins andmaintaining
cellular integrity in many bacterial spe-
cies, including mycobacteria. The Clp
complex degrades unfolded or mistrans-
lated proteins to maintain protein quality
and degrades specific proteins involved
in environmental adaptation. The Clp
complex has two components: the
proteolytic subunit (ClpP) and the regu-
latory ATPase subunit (ClpC/X). Protein
substrates are recognized by ClpC/X,
sometimes in association with accessory
proteins, unfolded using energy from
ATP hydrolysis, and directed into the
proteolytic cavity where degradation
occurs (Figure 1).M. tuberculosis has two ClpP subunits
(ClpP1 and ClpP2) that function together
with two regulatory ATPases (ClpC1 and
ClpX). The central proteolytic core con-
tains both ClpP1 and ClpP2 arranged in
two heptameric rings, which associate
with the multimeric ATPase rings (Alko-
pian et al., 2012). The Clp complex is
essential for M. tuberculosis viability
in vitro (Ollinger et al., 2012), as well as
during conditions mimicking infection,
for example during infection of macro-
phages (Estorninho et al., 2010) or after
recovery from hypoxic conditions (reacti-
vation) (Sherrid et al., 2010).
The authors beganwith thepremise that
screening for mycobacterium-specific
compounds would be likely to identify
novel natural products, an approach
borne out by their results. A relatively
high hit rate against M. tuberculosis of
10% (2% being specific) was obtained
froma library of extracts of soil organisms,
as compared to an expected hit rate for
small molecule libraries of 1%. The identi-
fication of natural products from extracts
can be problematic, but, in this case, the
authors were fortunate to find a single
product that retained potent activity. The
molecule lassomycin was identified and
characterized, and its potential biosyn-
thetic pathway was found. Lassomycin
has an excellent specificity for mycobac-
teria, with bactericidal activity against
both actively growing and stationary
phase bacteria. The activity against sta-
tionary phase bacteria is of particular
interest, because many antibiotics have
reduced activity under these settings
and such agents are thought likely to
reduce antibiotic tolerance/resistance
and have the potential to shorten therapy.
Interestingly the target for lassomycin is
the ClpC1 ATPase, and the unusual modeChemistry & Biology 21, April 24, 2014of action appears to be via a decoupling of
ATPase activity and proteolytic activity,
with the outcome being pronounced acti-
vation of ATPase activity and a concomi-
tant loss of proteolytic activity within the
Clp complex. Two other antibacterial
agents are known to have activity against
theM. tuberculosisClp complex; the acyl-
depsipeptides activate ClpP (Kirstein
et al., 2009), and cyclomarin A appears
to activate ClpC1 (Schmitt et al., 2011),
causing runaway protein degradation in
both cases. The observation that three
antibiotics work via mechanisms that do
not strictly target inhibition is certainly
worth further study. Disregulation of the
proteolytic process is the common factor,
suggesting that Clp proteolysis is tightly
controlled so that inhibition or activation
has the same outcome (cell death).
Lassomycin-induced cell death could
result from ATP depletion or the accumu-
lation of protein substrates. Both mecha-
nisms are plausible: (1) depletion of ATP
causes bacterial death under replicating
and nonreplicating conditions, as demon-
strated by the new antitubercular agent
bedaquiline, which targets the ATP syn-
thase; and (2) recently, Raju et al. (2014)
demonstrated that accumulation of spe-
cific proteins, in particular the regulator
WhiB1, resulting from depletion of ClpP2
is toxic. Clp is well known to be involved
in degradation of SsrA-tagged proteins
during trans-translation, but there is
evidence it also degrades untagged pro-
teins, and the two proteolytic subunits
appear to have different specificities (Per-
sonne et al., 2013). It would be interesting
to determine whether lassomycin acts via
disruption of the degradation of tagged or
untagged proteins.
There is a dearth of truly validated drug

















Figure 1. Schematic Diagram of the Clp Complex
(A) The Clp complex is comprised of the ClpP proteolytic subunits and the ClpC ATPase regulatory sub-
unit. Proteolysis is a three step process involving substrate recognition, unfolding, and translocation by
ClpC and proteolysis by ClpP in the central chamber.
(B) Lassomycin promotes ATP hydrolysis but prevents protein degradation.
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validation to demonstrate that target inhi-
bition is lethal (and feasible) is lacking. To
this end, a chemical biology approach in
which the targets of active compounds
are identified has been fruitful. The identi-
fication of ClpC1 as the target for lasso-
mycin is a welcome addition to the list
and adds further weight to the idea that
proteases are viable TB drug targets.
Further work to screen for natural prod-
ucts or small molecule inhibitors of prote-
ases would be of value.
The potential biosynthetic pathway for
lassomycin was identified in the producer
strain, paving the way for semisynthetic
approaches to analog generation or syn-438 Chemistry & Biology 21, April 24, 2014 ªthetic biology to generate alternative
versions by modular synthesis. It remains
to be seen if lassomycin itself is a viable
starting point for drug discovery, but it is
encouraging that it shows remarkable
specificity, with activity only against
mycobacterial ClpC1 and not against
other bacterial ClpC homologs or eukary-
otic proteases. This shows that ClpC can
be a specific target and other leads for
drug development might be identified
with similar specificity.
Interesting questions remain to be
answered regarding the mode of action
of lassomycin and could lead to a greater
understanding of processes underpinning
persistence or regrowth, for example,2014 Elsevier Ltd All rights reservedwork to address the metabolic conse-
quences such as ATP depletion and/or
toxic protein accumulation. Using lasso-
mycin as a probe for Clp function inmyco-
bacteria could also lead to information on
Clp substrates in different physiological
states. Experimental verification of the
lassomycin binding site to ClpC1 awaits
co-crystallization but would assist to
determine tractability of both this mole-
cule and the target for drug development.
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